I think your numbers are very conservative, based on what they've suggested the business metrics would be. Your assumed margins way too low. They suggest 90%, but let's then factor in corporate overheads (currently a rounding error on potential revenue but would likely increase with business growth). Same with treatment cost which will be much higher. But they are not likely to treat 100% of the cohort, so there's some swings and roundabouts.
The numbers can point to a very exciting outcome but are so far away from the current sp that talking about them seems like crazy talk.
Lots can happen between now and then and the COS is not 100%, so I'm happy to watch them take it one step at a time and if they do deliver, then I think shareholders will be handsomely rewarded.
PYC Price at posting:
13.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)